A Phase I Trial to Evaluate the Safety of the Addition of Alisertib to Fulvestrant in Women With Advanced Hormone Receptor Positive (HR+) Breast Cancer

Trial Profile

A Phase I Trial to Evaluate the Safety of the Addition of Alisertib to Fulvestrant in Women With Advanced Hormone Receptor Positive (HR+) Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs Alisertib (Primary) ; Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Mar 2016 Status changed from suspended to active, no longer recruiting as per ClinicalTrials.gov record.
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium (n = 10).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top